Premium
Comparison of gentamicin and tobramycin nephrotoxicity in patients receiving individualized‐pharmacokinetic dosing regimens
Author(s) -
Pancorbo Salvador,
Compty Christina,
Heissler Joseph
Publication year - 1982
Publication title -
biopharmaceutics and drug disposition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.419
H-Index - 58
eISSN - 1099-081X
pISSN - 0142-2782
DOI - 10.1002/bdd.2510030111
Subject(s) - tobramycin , nephrotoxicity , aminoglycoside , medicine , gentamicin , pharmacokinetics , dosing , creatinine , pharmacology , trough level , renal function , urology , antibiotics , toxicity , tacrolimus , transplantation , chemistry , biochemistry
The incidence of nephrotoxicity has been studied in 175 patients who received either gentamicin or tobramycin. All patients received individualized dosing regimens of the drugs based on pharmacokinetic parameters measured after the initial dose. Subsequent doses were calculated from the pharmacokinetic data to produce peak aminoglycoside levels of between 6 and 8 μg ml −1 and trough levels that were below 2 μg ml −1 . Renal toxicity was defined as a 30 per cent or greater increase in the serum creatinine level above the baseline value. Five of the 125 patients (4 per cent) who received gentamicin, and 1 of the 39 patients (2.6 per cent) who received tobramycin developed signs of nephrotoxicity. This difference was not statistically significant.